You Can Now Inject Yourself With an Alzheimer’s Drug at Home

You Can Now Inject Yourself With an Alzheimer’s Drug at Home

Self-testing and self-treating are becoming bigger trends in medicine, and now, you can conduct part of your treatment at home by yourself if you have Alzheimer’s disease. On Aug. 30, the U.S. Food and Drug Administration (FDA) approved the first at-home treatment for Alzheimer’s. Lecanemab, sold under the brand name Leqembi—which the FDA approved in 2023 as the first medication to treat the memory disorder—is now available in a self-injecting p…

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help...

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status – EastMud

TOKYO and CAMBRIDGE, Mass., Sept. 3, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-…

First-Ever At-Home Injection Treatment: BioArctic's Leqembi Could Transform Early Alzheimer's Care

BioArctic initiates FDA rolling submission for Leqembi Iqlik subcutaneous autoinjector, offering 15-second at-home administration for early Alzheimer's treatment. Now approved in 48 countries.